GlassScriptPhysician profile
Dhriti Das
NPI 1427553569
$7,327.77
in general payments reported to CMS, 2019-2025
42 companies · $3,141 in 2025
The $3,141 reported for 2025 was more than what 84% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.86 · 2021: $38.83 · 2023: $905 · 2024: $3,229 · 2025: $3,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,255 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,254.86 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $856.04 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $594.94 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $577.32 | 2023-2025 | Evenity, Prolia, Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $411.69 | 2023-2025 | |
| Beta Bionics, INC. | $368.90 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Sanofi-Aventis U.S. LLC | $358.21 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $343.89 | 2023-2025 | |
| Dexcom, INC. | $318.48 | 2023-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $297.97 | 2023-2025 | Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.08 | 2023-2025 | Jardiance |
| Antares Pharma, INC. | $221.54 | 2024-2025 | Xyosted |
| Mannkind Corporation | $219.29 | 2023-2025 | Afrezza |
| Recordati_rare_diseases_inc. | $210.61 | 2023-2025 | Isturisa, Signifor Lar |
| Alexion Pharmaceuticals, INC. | $193.13 | 2023-2025 | Strensiq |
| Radius Health, INC. | $190.81 | 2023-2025 | Tymlos |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $182.43 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $176.90 | 2023-2025 | Unithroid |
| Corcept Therapeutics | $174.22 | 2024-2025 | Korlym |
| Ibsa Pharma INC. | $158.95 | 2023-2025 | Tirosint, Licart, Tirosint |
| Astellas Pharma US INC | $117.24 | 2024-2025 | Veozah |
| Neurocrine Biosciences, INC. | $110.40 | 2024-2025 | |
| Tandem Diabetes Care, INC. | $99.38 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Nevro Corp. | $94.80 | 2023-2024 | Senza |
| Madrigal Pharmaceuticals | $94.33 | 2025 | Rezdiffra |
| Ascendis Pharma Endocrinology INC | $92.00 | 2025 | Yorvipath |
| Globus Medical, INC. | $67.27 | 2025 | Senza |
| Xeris Pharmaceuticals, INC. | $67.08 | 2023-2025 | Gvoke Hypopen |
| Medtronic, INC. | $59.40 | 2024-2025 | Minimed 780g |
| Sequel Med Tech, LLC | $47.12 | 2025 | Twiist |
| Kyowa Kirin, INC. | $45.26 | 2024 | Crysvita |
| Ultragenyx Pharmaceutical INC. | $41.83 | 2023-2024 | Crysvita, Crysvita |
| Ucb, INC. | $38.83 | 2021 | |
| Halozyme INC | $36.55 | 2023 | |
| Pfizer INC. | $33.80 | 2023-2024 | |
| Boston Scientific Corporation | $29.16 | 2025 | General - Pain Management |
| Cardinal Health 414 LLC | $28.12 | 2024 | |
| Verity Pharmaceuticals INC. | $22.48 | 2025 | Tlando |
| Averitas Pharma INC. | $22.15 | 2025 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.56 | 2024 | Cycloset |
| Avvisto Therapeutics, LLC | $15.77 | 2025 | Cycloset |
| Tolmar, INC. | $14.98 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $13.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dhriti Das listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.